Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Noordhuis

Showing results (11-20 of 44) with videos related to

Pageof 5
Sort By:
Leukemia Research|July 21, 1998
Modulation of resistance to ara-C by bryostatin in fresh blast cells from patients with AMLA W Elgie, J M Sargent, P Alton, et al.
European Journal of Cancer (Oxford, England : 1990)|September 23, 2000
Cross-resistance in the 2',2'-difluorodeoxycytidine (gemcitabine)-resistant human ovarian cancer cell line AG6000 to standard and investigational drugsA M Bergman, G Giaccone, C J van Moorsel, et al.
Molecular Pharmacology|April 1, 1999
Multiple mechanisms of resistance to polyglutamatable and lipophilic antifolates in mammalian cells: role of increased folylpolyglutamylation, expanded folate pools, and intralysosomal drug sequestrationG Jansen, H Barr, I Kathmann, et al.
Biochemical and Biophysical Research Communications|February 5, 2003
Rapid disappearance of deoxyribose-1-phosphate in platelet derived endothelial cell growth factor/thymidine phosphorylase overexpressing cellsM de Bruin, K Smid, A C Laan, et al.
British Journal of Cancer|October 1, 1993
In vitro antitumour activity of cis- and trans-5-fluoro-5,6-dihydro-6-alkoxy-uracils; effects on thymidylate synthesisC L van der Wilt, G W Visser, B J Braakhuis, et al.
International Journal of Cancer|May 28, 1993
Transformation of mouse fibroblasts with the oncogenes H-ras OR trk is associated with pronounced changes in drug sensitivity and metabolismG J Peters, M Wets, Y P Keepers, et al.
Journal of Chemotherapy (Florence, Italy)|April 17, 2007
Clinical phase I and pharmacology study of gemcitabine (2', 2'-difluorodeoxycytidine) administered in a two-weekly scheduleG J Peters, M Clavel, P Noordhuis, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1996
Antitumor activity of prolonged as compared with bolus administration of 2',2'-difluorodeoxycytidine in vivo against murine colon tumorsG Veerman, V W Ruiz van Haperen, J B Vermorken, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 1, 1996
Therapeutic efficacy of fluoropyrimidines depends on the duration of thymidylate synthase inhibition in the murine colon 26-B carcinoma tumor modelJ A van Laar, C L van der Wilt, Y M Rustum, et al.
Nucleosides, Nucleotides & Nucleic Acids|December 2, 2004
Comparison of mRNA expression levels determined with TaqMan and competitive template RT-PCRR Mauritz, W Schwabe, P Haeusler, et al.
Pageof 5

Showing results (11-20 of 44) with videos related to

Sort By:
Pageof 5
Leukemia Research|July 21, 1998
Modulation of resistance to ara-C by bryostatin in fresh blast cells from patients with AMLA W Elgie, J M Sargent, P Alton, et al.
European Journal of Cancer (Oxford, England : 1990)|September 23, 2000
Cross-resistance in the 2',2'-difluorodeoxycytidine (gemcitabine)-resistant human ovarian cancer cell line AG6000 to standard and investigational drugsA M Bergman, G Giaccone, C J van Moorsel, et al.
Molecular Pharmacology|April 1, 1999
Multiple mechanisms of resistance to polyglutamatable and lipophilic antifolates in mammalian cells: role of increased folylpolyglutamylation, expanded folate pools, and intralysosomal drug sequestrationG Jansen, H Barr, I Kathmann, et al.
Biochemical and Biophysical Research Communications|February 5, 2003
Rapid disappearance of deoxyribose-1-phosphate in platelet derived endothelial cell growth factor/thymidine phosphorylase overexpressing cellsM de Bruin, K Smid, A C Laan, et al.
British Journal of Cancer|October 1, 1993
In vitro antitumour activity of cis- and trans-5-fluoro-5,6-dihydro-6-alkoxy-uracils; effects on thymidylate synthesisC L van der Wilt, G W Visser, B J Braakhuis, et al.
International Journal of Cancer|May 28, 1993
Transformation of mouse fibroblasts with the oncogenes H-ras OR trk is associated with pronounced changes in drug sensitivity and metabolismG J Peters, M Wets, Y P Keepers, et al.
Journal of Chemotherapy (Florence, Italy)|April 17, 2007
Clinical phase I and pharmacology study of gemcitabine (2', 2'-difluorodeoxycytidine) administered in a two-weekly scheduleG J Peters, M Clavel, P Noordhuis, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1996
Antitumor activity of prolonged as compared with bolus administration of 2',2'-difluorodeoxycytidine in vivo against murine colon tumorsG Veerman, V W Ruiz van Haperen, J B Vermorken, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 1, 1996
Therapeutic efficacy of fluoropyrimidines depends on the duration of thymidylate synthase inhibition in the murine colon 26-B carcinoma tumor modelJ A van Laar, C L van der Wilt, Y M Rustum, et al.
Nucleosides, Nucleotides & Nucleic Acids|December 2, 2004
Comparison of mRNA expression levels determined with TaqMan and competitive template RT-PCRR Mauritz, W Schwabe, P Haeusler, et al.
Pageof 5